[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ascendis Pharma Endocrinology Division A\u002FS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100502316","a-us-non-interventional-effectiveness-and-safety-study-of-patients-treated-with-skytrofa-100502316",false,"NCT05820672","A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA","A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)","SkybriGHt","Inclusion Criteria:\n\n* Patients who are on treatment with SKYTROFA (lonapegsomatropin)\n* Patients being clinically managed in USA\n* Patients with an appropriate written informed consent\u002Fassent as applicable for the age of the patient\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical study","ALL",{"count":19,"type":20},900,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care",[25],"Growth Hormone Deficiency",[27,28],"Human Growth Hormone","SKYTROFA","RECRUITING","2026-04-20",{"date":32,"type":33},"2026-04-21","ACTUAL",{"date":35,"type":33},"2023-03-20",{"date":37,"type":20},"2033-03",{"name":39,"class":40},"Ascendis Pharma Endocrinology Division A\u002FS","INDUSTRY",27,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":73,"locationsCount":41},"100498843","a-post-authorisation-safety-study-pass-of-patients-treated-with-lonapegsomatropin-100498843","NCT05775523","A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","SkyPASS","Inclusion Criteria:\n\n* Paediatric patients with GHD who are on treatment with lonapegsomatropin\n* Patients being clinically managed in Europe or the USA\n* Appropriate written informed consent\u002Fassent as applicable for the age of the patient\n* Patients willing to comply with follow-up requirements of the study\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical trial for short stature\n* Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment\n* Patients for whom treatment with lonapegsomatropin is contraindicated\n* Patients with closed epiphyses\n* Patients with active malignant tumours\n* Patients under antitumour therapy within the past 12 months prior to instituting GH therapy\n* Hypersensitivity to somatropin or any of the excipients in lonapegsomatropin","1 Year","18 Years",{"count":53,"type":20},500,"The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.",[25],[27,57,58,59,60,61,62,63,64,65,25,66,67,48],"hGH","rhGH","GHD","Long Acting Growth Hormone","Lonapegsomatropin","Prodrug","Growth Failure","Growth Hormone Replacement Therapy","Sustained Release Growth Hormone","TransCon hGH","Skytrofa","2026-02-02",{"date":70,"type":33},"2026-02-04",{"date":35,"type":33},{"date":37,"type":20},{"name":39,"class":40},""]